Dis-Chem Pharmacies Management
Management criteria checks 4/4
Dis-Chem Pharmacies' CEO is Rui Morais, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is ZAR16.70M, comprised of 74.8% salary and 25.2% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth ZAR311.51M. The average tenure of the management team and the board of directors is 2.4 years and 3.9 years respectively.
Key information
Rui Morais
Chief executive officer
R16.7m
Total compensation
| CEO salary percentage | 74.8% |
| CEO tenure | 1.4yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.4yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Is Dis-Chem Pharmacies (JSE:DCP) Using Too Much Debt?
Nov 27
Shareholders Are Optimistic That Dis-Chem Pharmacies (JSE:DCP) Will Multiply In Value
Nov 10These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well
Aug 21Shareholders Should Be Pleased With Dis-Chem Pharmacies Limited's (JSE:DCP) Price
Jun 06Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around
Apr 17Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly
Feb 26Dis-Chem Pharmacies (JSE:DCP) Might Be Having Difficulty Using Its Capital Effectively
Dec 30If EPS Growth Is Important To You, Dis-Chem Pharmacies (JSE:DCP) Presents An Opportunity
Sep 07Here's Why Dis-Chem Pharmacies (JSE:DCP) Can Manage Its Debt Responsibly
Aug 16Dis-Chem Pharmacies (JSE:DCP) Will Want To Turn Around Its Return Trends
Jul 31Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
May 09There Are Reasons To Feel Uneasy About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
Mar 29Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?
Jan 14Returns On Capital At Dis-Chem Pharmacies (JSE:DCP) Paint A Concerning Picture
Nov 04Dis-Chem Pharmacies Limited (JSE:DCP) Shares Could Be 24% Below Their Intrinsic Value Estimate
Oct 04We Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease
Sep 01Some Investors May Be Worried About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital
Jul 04A Look At The Fair Value Of Dis-Chem Pharmacies Limited (JSE:DCP)
Jun 21Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet
Jun 08The Dis-Chem Pharmacies Limited (JSE:DCP) Yearly Results Are Out And Analysts Have Published New Forecasts
May 25Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?
Feb 23Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings
Feb 08I Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease
Dec 13Dis-Chem Pharmacies' (JSE:DCP) Strong Earnings Are Of Good Quality
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | R1b |
| May 31 2024 | n/a | n/a | R1b |
| Feb 29 2024 | R17m | R12m | R984m |
| Nov 30 2023 | n/a | n/a | R942m |
| Aug 31 2023 | n/a | n/a | R899m |
| May 31 2023 | n/a | n/a | R949m |
| Feb 28 2023 | R18m | R12m | R1b |
| Nov 30 2022 | n/a | n/a | R1b |
| Aug 31 2022 | n/a | n/a | R1b |
| May 31 2022 | n/a | n/a | R946m |
| Feb 28 2022 | R14m | R11m | R853m |
| Nov 30 2021 | n/a | n/a | R815m |
| Aug 31 2021 | n/a | n/a | R776m |
| May 31 2021 | n/a | n/a | R722m |
| Feb 28 2021 | R6m | R6m | R669m |
| Nov 30 2020 | n/a | n/a | R655m |
| Aug 31 2020 | n/a | n/a | R641m |
| May 31 2020 | n/a | n/a | R620m |
| Feb 29 2020 | R6m | R6m | R598m |
| Nov 30 2019 | n/a | n/a | R573m |
| Aug 31 2019 | n/a | n/a | R549m |
| May 31 2019 | n/a | n/a | R634m |
| Feb 28 2019 | R5m | R5m | R719m |
| Nov 30 2018 | n/a | n/a | R718m |
| Aug 31 2018 | n/a | n/a | R718m |
| May 31 2018 | n/a | n/a | R701m |
| Feb 28 2018 | R7m | R5m | R684m |
Compensation vs Market: Rui's total compensation ($USD911.51K) is about average for companies of similar size in the ZA market ($USD1.08M).
Compensation vs Earnings: Rui's compensation has been consistent with company performance over the past year.
CEO
Rui Morais (40 yo)
1.4yrs
Tenure
R16,702,000
Compensation
Mr. Rui Manuel Morais, CA(SA) has been the Chief Executive Officer at Dis-Chem Pharmacies Limited since July 01, 2023 and its Executive Director since August 13, 2012. He served as Chief Financial Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.4yrs | R16.70m | 0.99% ZAR 311.5m | |
| CFO & Executive Director | 1.4yrs | R5.19m | no data | |
| Executive Director | 1.5yrs | R18.45m | no data | |
| Managing Director | 19.6yrs | R14.97m | no data | |
| Executive Director | 2.4yrs | R7.56m | 0.72% ZAR 227.4m | |
| Executive Director | 2.4yrs | R7.58m | 4.07% ZAR 1.3b | |
| Prescribed Officer | no data | R7.81m | no data | |
| Commercial Director | no data | R15.38m | 0.0045% ZAR 1.4m | |
| Prescribed Officer | no data | R4.61m | 0.0012% ZAR 368.0k | |
| Prescribed Officer | no data | R5.11m | no data | |
| Human Resources Director | no data | no data | no data | |
| Company Secretary | 3.8yrs | no data | no data |
2.4yrs
Average Tenure
67yo
Average Age
Experienced Management: DCP's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 12.3yrs | R16.70m | 0.99% ZAR 311.5m | |
| CFO & Executive Director | 1.4yrs | R5.19m | no data | |
| Executive Director | 19.6yrs | R18.45m | no data | |
| Executive Director | 2.4yrs | R7.56m | 0.72% ZAR 227.4m | |
| Executive Director | 2.4yrs | R7.58m | 4.07% ZAR 1.3b | |
| Independent Non-Executive Chairman | 8.2yrs | R3.34m | 0.058% ZAR 18.3m | |
| Independent Non-Executive Director | 8.2yrs | R967.00k | 0.0095% ZAR 3.0m | |
| Independent Non-Executive Director | 8.2yrs | R691.00k | 0.019% ZAR 5.9m | |
| Independent Non-Executive Director | 3.9yrs | R750.00k | no data | |
| Non-Independent Non Executive Director | 3.1yrs | R560.00k | no data | |
| Independent Non-Executive Director | 2.4yrs | R788.00k | no data |
3.9yrs
Average Tenure
53.5yo
Average Age
Experienced Board: DCP's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dis-Chem Pharmacies Limited is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Dias | Arqaam Capital Research Offshore S.A.L. |
| Michael de Nobrega | Avior Capital Markets |
| Paul Henri Steegers | BofA Global Research |